Indeed, our results also suggest that the mechanism of the metabolic advantage mediated by the N-cadherin-IL-8-AKT-mTOR pathway observed in our study may provide a helpful explanation for the development of immunosuppressive therapy in prostate cancer. The gene discussed is CXCL8; the disease is prostate carcinoma.